Haleon plc (HLN): what the price assumes

In the published model solve dated 2026-Q2, anchored at $9.95, Haleon plc (HLN) is priced for -2.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/HLN

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.2% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.2pp.

Reconcile: at the x-ray's 9.3% required return this reads ~11.4%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.6%); the inversion above states its own rate.

Per-Model Detail (n=17)

Solvency

Bullet Takeaways

• Haleon is a pure-play consumer-health company built on category-leading brands across Oral Health, vitamins, Pain Relief, Respiratory, and Digestive Health, with Sensodyne and parodontax delivering double-digit growth in the most recent quarter on innovation and geographic expansion.
• The biggest near-term risk is volume: organic revenue grew just 2.2% in Q1 2026 with price up 2.4% and volume down 0.2%, meaning the top line is being carried by pricing rather than by people buying more.
• Watch whether growth accelerates into the back half as guided; full-year organic revenue guidance is 3% to 5% with high-single-digit adjusted operating-profit growth at constant currency, and a normal cold-and-flu season would remove a roughly 130 basis point headwind.

Bull Case

The moat here is shelf space and habit. Haleon owns brands that sit in medicine cabinets for years, Sensodyne for sensitive teeth, parodontax for gums, Centrum for vitamins, Panadol for pain, and consumers reach for them by name rather than comparing labels. That brand pull is the structural advantage, and it shows up where it matters: the Oral Health portfolio kept strong momentum in Q1 2026, with innovation and geographic expansion driving double-digit growth in both Sensodyne and parodontax even as the overall market was soft. A power brand that can grow double digits while the category is sluggish is demonstrating exactly the pricing power that defines a consumer-health franchise.

The economics behind those brands are genuinely good. The business runs at an operating margin around 19%, the kind of profitability that comes from selling branded everyday-health products at prices well above their cost to make, and it sits within a peer set of the largest consumer-staples names, Kenvue, Procter & Gamble, Unilever, Colgate. Pricing did the heavy lifting in the quarter, up 2.4%, which is what a portfolio of trusted brands is supposed to be able to do: pass through cost and protect margin without losing the customer.

The debt is manageable and the geographic spread gives the recovery multiple paths. Net debt sits around $8.5 billion but only about 0.8 times operating income, with interest covered roughly six times over, so this is a stable balance sheet rather than a stretched one. Emerging markets grew organic revenue 4.3% in the quarter despite a weaker macro backdrop, and management expects growth to accelerate through the remainder of the year toward its 3% to 5% full-year range. The bull case is a defensive compounder: durable brands, healthy margins, a sound balance sheet, and a guided reacceleration once the weak cold-and-flu season laps.

Bear Case

The uncomfortable fact for a holder is that the growth a consumer-health stock is supposed to deliver, more units sold, is not what is showing up. In Q1 2026 the entire 2.2% organic revenue gain came from price; volume actually fell 0.2%. For a branded staples company, persistent volume declines masked by price increases are the warning sign, because pricing power has a ceiling. Push price too far and value-conscious consumers trade down to private label or store brands, and the very brand pull that justifies the premium starts to erode at the margin.

That dynamic collides with the price. At roughly 28 times operating income, Haleon trades richly against every standard frame: the asset, earnings-power, peer-multiple, and even forward-growth lenses all sit below the current price. The price embeds operating-profit growth near 13.7% a year, and yet the company itself guides to high-single-digit adjusted operating-profit growth and only 3% to 5% organic revenue growth for the year. When the market's implied requirement runs roughly double management's own guided pace, the gap is the bear case: the stock is priced for an acceleration the company is not promising.

The operating backdrop is not helping in the near term. A weak cold-and-flu season took an estimated 130 basis points off the quarter, North America grew just 1.0%, and emerging-markets strength reflected a weaker macro backdrop in places like Brazil. These are not disasters, but they are reminders that a consumer-health portfolio is exposed to the seasonal respiratory cycle, currency swings, and consumer wallets in a way that makes the guided second-half acceleration a hope rather than a certainty. The bear case does not need Haleon to stumble badly; it needs only for a high-single-digit-growth business to keep being priced as a low-teens compounder, and for volume to keep going the wrong way.

Valuation

Haleon trades around 28 times operating income, and the inversion reads that price as a bet on operating-profit growth near 13.7% a year for five years. The tension is immediate: the company's own full-year guidance is for high-single-digit adjusted operating-profit growth and 3% to 5% organic revenue growth. The price, in other words, is asking for roughly double what management is guiding to, and that gap is the heart of the valuation.

The families of method all point the same direction, which is unusual and worth weighing. None of them reach the current price: the asset-based, earnings-power, peer-multiple, and even the forward-growth lenses all land below it. When every standard frame sits under the price, the stock is being valued for quality and defensiveness, the premium investors pay for a portfolio of recession-resistant brands, rather than for any cash-flow math that supports the level.

The balance sheet is the steadying element. Net debt around $8.5 billion is only about 0.8 times operating income, interest is covered roughly six times, and the operating margin near 19% generates dependable cash. This is not a leverage story; it is a multiple story. The question the valuation poses is not whether Haleon survives, which is not in doubt, but whether a stable, high-single-digit-growth consumer-health business deserves a low-teens-growth price tag. The methods say it is paying up for durability; whether that durability is worth the premium is the judgment the buyer is making.

Catalysts

The Q1 2026 trading update set a modest tone with a guided improvement to come. Organic revenue grew 2.2%, with price up 2.4% and volume down 0.2%, held back by a weak cold-and-flu season estimated at about 130 basis points of drag. Regionally, North America grew 1.0% and emerging markets 4.3% against a softer macro backdrop, while Oral Health stood out as Sensodyne and parodontax posted double-digit growth on innovation and geographic expansion, including the rollout of the Sensodyne Clinical platform and Panadol Dual Action.

The forward catalyst is the guided second-half acceleration. Management reaffirmed full-year organic revenue growth of 3% to 5%, with growth expected to pick up over the remainder of the year, and high-single-digit adjusted operating-profit growth at constant currency. The cleanest checkpoints are the next trading updates and a normal respiratory season, which would lift the roughly 130 basis point headwind that depressed the first quarter. The key things to watch are whether volume turns positive rather than relying on price, and whether the Oral Health momentum broadens to the other categories; those two signals decide whether the back-half reacceleration is real.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• KVUE (Kenvue Inc.)
• FY2025 10-K: …2) global CPG companies that operate in similar or adjacent categories, 3) regional companies that operate in our categories within the markets in which we compete, 4) generic OTC manufacturers and retailers', including our customers', private-label brands in both traditional retail and online, and 5) emerging…
• FY2025 10-K: Care (Digestive Health, Smoking Cessation, Eye Care, and Other) Skin Health and Beauty Face and Body Care Hair, Sun, and Other Essential Health Oral Care Baby Care Other Essential Health (Women's Health, Wound Care, and Other) The Company's product categories as a percentage of Net sales for the fiscal twelve months…
• PG (PROCTER & GAMBLE CO)
• FY2025 10-K: …innovation) was offset by declines in Greater China and Asia Pacific (both due to market contraction). Organic sales increased low single digits driven by low single-digit increases in North America and Europe, partially offset by a high single-digit decline in IMEA. Global market share of the fabric care category…
• FY2025 10-K: …increase, partially offset by unfavorable foreign exchange. The unit volume increase was due to increases in North America (due to share growth) and Latin America (due to market growth). Organic sales increased mid-single digits due to double-digit growth in Latin America, mid-single-digit growth in Europe and low…
• CL (COLGATE-PALMOLIVE COMPANY)
• FY2025 10-K: 2024 was primarily due to decreases in Oral Care and Personal Care organic sales. The decrease in Oral Care was primarily due to an organic sales decline in the toothpaste category, partially offset by organic sales growth in the manual toothbrush category. The decrease in Personal Care was primarily due to an organic…
• FY2025 10-K: …omni-channel demand generation; leading in capabilities such as data, analytics and AI; and evolving our high-impact, inclusive culture are the keys to accelerating growth going forward. Our commitment to these priorities, the strength of our brands, our resilient global supply chain, the breadth of our global…
• UL (UNILEVER PLC)
• FY2025 20-F: Strategic Report Unilever Annual Report on Form 20-F 2025 43 OUR PERFORMANCE UNDERLYING OPERATING PROFIT AND UNDERLYING OPERATING MARGIN Underlying operating profit and underlying operating margin mean operating profit and operating margin before the impact of non- underlying items within operating profit. Underlying…
• FY2025 20-F: …models. For example, by producing key materials like surfactants and designing fragrances in-house, we are improving supply resilience and securing long-term cost benefits. We are also co-locating distribution centres with factories, enabling faster, more direct deliveries to customers. This year, we opened a new…
• EL (Estee Lauder Companies Inc)
• FY2025 10-K: …subsidies in China. 41 Table of Contents OPERATING RESULTS Year Ended June 30, ($ in millions) 2025 2024 As Reported: Operating (loss) income $ (785) $ 970 $ Change from prior year (1,755) (539) % Change from prior year (100+)% (36) % Operating Margin (5.5) % 6.2 % Non-GAAP Financial Measure (1) : % Change in…
• FY2025 10-K: Product Categories and Geographic Regions exclude the fiscal 2025 and fiscal 2024 impacts of returns/(return adjustments) associated with restructuring and other activities of approximately $(3) million and $1 million, respectively. Product Categories Reported net sales for our product categories for the years ended…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.